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Many tissues contain adult mesenchymal stem cells (MSCs), which may be used in tissue regeneration therapies. However, the
MSC availability in most tissues is limited which demands expansion in vitro following isolation. Like many developing cells, the
state of MSCs is affected by the surrounding microenvironment, and mimicking this natural microenvironment that supports
multipotent or differentiated state in vivo is essential to understand for the successful use of MSC in regenerative therapies. Many
researchers are, therefore, optimizing cell culture conditions in vitro by altering growth factors, extracellular matrices, chemicals,
oxygen tension, and surrounding pH to enhance stem cells self-renewal or differentiation. Insulin-like growth factors (IGFs) system
has been demonstrated to play an important role in stem cell biology to either promote proliferation and self-renewal or enhance
differentiation onset and outcome, depending on the cell culture conditions. In this review, we will describe the importance of IGFs,
IGF-1 and IGF-2, in development and in the MSC niche and how they affect the pluripotency or differentiation towards multiple
lineages of the three germ layers.
1. Introduction
Currently, many diseases associated with organ failure and
degeneration which are untreatable by pharmaceuticals or
organ replacement have seen the promise in cell-replacement
and tissue regeneration therapies [1]. Such diseases include
endocrine (diabetes), neurodegenerative diseases (Parkin-
son’s, Alzheimer’s, and Huntington’s), and cardiovascular
diseases (myocardial infarction and peripheral vascular
ischemia) and injuries or chronic conditions in the cornea,
skeletal muscle, skin, joints, and bones [2]. Stem cells have
the potential for tissue/organ repair, replacement of dying
cells, and promoting the survival of damaged tissues [3]. In
addition, with the ability to generate induced pluripotent
stem cells from the recipient’s own somatic cells [4–6] and the
availability of new gene editing technologies (e.g., CRISPR-
Cas9 and TALEN) [7, 8], the use of stem cells inmany genetic
and acquired diseases is closer to reality in the near future.
Adult mesenchymal stem cells (MSCs) are multipotent
cells with a defined capacity for self-renewal and differentia-
tion into cell types of all three germ layers depending on their
origin. Unlike embryonic stem cells, MSCs have less ethical
controversies and lower tumorigenicity; however, they have
restricted differentiation potential [9]. Recent research has
also demonstrated a transdifferentiation ability ofMSCs from
cells of one germ layer to another [10]. In addition,MSCs have
an immunomodulatory effect to reduce an immune response
and are able to be engrafted successfully in therapy resistant
graft-versus-host disease [3]. The existence of multipotent
stem cells in adult tissues was first described by Till and
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McCulloch in 1961 [11] and was followed by the isolation
of MSCs from bone marrow by Friedenstein in 1968 [12].
Since then, MSCs have been isolated from most mature
organs and tissues including skeletal muscle [13], adipose
tissue [14], deciduous teeth [15], umbilical cord blood and
placenta [16], peripheral blood [17], and brain [18]. Several
biological markers characterize MSCs of different origins to
be positive for CD73, CD105, CD29, CD44, CD71, CD90,
CD106, CD120a, and CD124 and negative for CD117, CD34,
CD45, and CD14 [19–21]. MSCs have been demonstrated to
differentiate predominantly into mesodermal cells including
osteogenic, chondrogenic, adipogenic [22], and endothelial
[23] lineages. Also, MSCs can differentiate towards ectoder-
mal lineages including corneal [24, 25] andneuronal cells [26]
and also can differentiate towards insulin-producing cells of
the endodermal endocrine pancreatic lineage [27].
Stem cell “niche” is a paracellular microenvironment
that includes cellular and noncellular components from
local and systemic sources that regulate stem cell pluripo-
tency or multipotency, proliferation, differentiation, survival,
and localization [28]. Stem cells are maintained by the
surrounding microenvironment via several cues including
physical, structural, neural, humoral, paracrine, autocrine,
and metabolic interactions [29]. Therefore, a combination
of different microenvironmental signals that are generated
during development, healing, or disease states is capable of
regulating the tissue regeneration process leading to prolif-
eration, differentiation, or quiescence [30]. In this review, we
will focus on the role of insulin-like growth factors (IGFs) in
the MSC niche (Figure 1).
2. Insulin-Like Growth Factor System: Ligands,
Receptors, and Binding Proteins
Insulin-like growth factors (IGFs; IGF-1 and IGF-2) are
two small polypeptides (∼7 kDa) that regulate survival, self-
renewal, and differentiation of many types of cells, including
stem cells [31]. In the systemic circulation in postnatal life,
IGF-1 levels are regulated by growth hormone (GH), which
induces IGF expression and is released by the liver and
accounts for 70–90% of circulating IGFs [32]. Knockdown of
Igf-1 from postnatal murine liver accounted for 75% reduc-
tion in circulating IGF-1 levels accompanied by a fourfold
increase in GH, which can lead to insulin resistance [33].
Even in the absence of hepatic IGF-1, postnatal growth is
not affected in mice. This is likely due to extrahepatic tissue
expression of IGFs in a paracrine/autocrine fashion, such as
in the bone, brain, lung, uterus, ovaries, adipose tissue, and
muscle [34]. Under this condition, serum IGF concentrations
are regulated by several factors including gender, age, and
nutrition status, leading to a variable range of IGF-1 (264–
789 ng/mL) and IGF-2 (702–1042 ng/mL) in healthy individ-
uals [35]. In prenatal (embryonic/fetal) life, the regulation of
the synthesis of IGF-1 and IGF-2 by many different organs
and tissues is less well understood. Most likely, the synthesis
is regulated by local (paracrine) factors and cues such as
nutrient status, oxygen tension, biochemistry, extracellular
matrix, and other growth factors in addition to endocrine
factors. Importantly, the IGFs are synthesized as required
by the developmental and physiological cues within the
extracellular and intracellular environment. It is likely that
the fate of mesenchymal stem cells which reside in the
paracellular niches in adult tissues is regulated by the tissue
microenvironment.
At the molecular level, IGF-1 shares more than 60%
sequence homology with IGF-2 and 50% with proinsulin
[42, 43]. IGFs signal mainly via the IGF-1 receptor (IGF-1R),
which has the highest binding affinity (Kd of 1 nM) towards
IGF-1, followed by 10-fold lower affinity to IGF-2 [44]. IGF-1R
is a receptor-tyrosine-kinase (RTK) which shares a structural
homology domain with the insulin receptor (IR). In turn,
IR is expressed in two isoforms, IR-A and IR-B, and can
form hybrid receptors (HR-A and HR-B) with the IGF-1R,
which binds to both IGFs with variable affinities [45]. Unlike
IGF-1, IGF-2 binds to its specific receptor, IGF-2R, and,
similar to insulin, it can bind to IR-A [46]. IGF-1R, IR, and
HRs are mitogenic RTKs, while IGF-2R is not. Therefore,
different receptor and ligand combinations can cause variable
signaling outcomes, especially in stem cells. Few studies
have been reported on the effects of IGF-1 on the growth,
differentiation, and migratory capacity of mesenchymal stem
cells [36, 38, 47]; however, the expression of different IGF
receptors, insulin receptors, and hybrid receptors and their
relative roles in pluripotency and differentiation have not
been well studied.
Circulating IGFs are bound to six soluble (∼30 kDa)
IGF-binding proteins (IGFBPs, 1–6), which determine the
bioavailability of free IGF ligand in the extracellular vicinity
of the receptors, thus modifying the IGF actions [48]. Under
normal physiological conditions, IGFs bind IGFBPs with
greater affinity than they bind IGF-1R [49–51]. IGFBPs
interaction with IGFs occurs via noncovalent binding [52]
that protects them from degradation by increasing their
half-life [53, 54] and facilitates delivery to specific tissues.
Therefore, IGFBPs play an important role in IGF-regulated
cell metabolism, development, and growth [55]. In addition,
it has become apparent that the IGFBPs can be expressed and
maintained within the cellular microenvironment and have
additional functions independent of regulating IGFs [56].
The role of IGFBPs in MSC fate is currently being delineated
and will be mentioned briefly in this review.
3. Insulin-Like Growth Factor System:
Signaling Cascades
IGF-1R is a transmembrane tetramer receptor that exists
as heterodimers composed of two 𝛼 and 𝛽 hemireceptors
linked by disulfide bonds in a 𝛽–𝛼–𝛼–𝛽 structure [57].
Upon ligand binding, the downstream signal of IGF-1R is
dependent on the differential phosphorylation pattern of its
𝛽-subunit and the resultant tyrosine residues available to
initiate mitogenic signals, mainly through the phosphoinosi-
tide 3-kinase (PI3K), AKT/PKB, and the extracellular signal-
regulated kinase (ERK1/2) [55, 58, 59]. In thismanner, IGF-1R
can induce transcriptional activity to promote survival, self-
renewal, and differentiation of MSCs [60, 61].
Upon activation of the extracellular 𝛼 subunits of the
IGF-1R, autophosphorylation in the tyrosine residues on
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Figure 1: Stem cell niche in vivo. The stem cell niche is a complex compartment surrounding mesenchymal stem cells (MSCs) directing
their identity preservation via cellular and acellular components. Various clues and signals are exchanged between MSCs, stromal cells, and
progenitor cells and the extracellular matrix containing different soluble factors, oxygen tension, and pH.Therefore, MSC niche manipulates
the stemness state of MSCs following growth and regeneration demand. IGFs can signal via paracrine/autocrine (produced locally by the
tissue) or endocrine (delivered by blood supply) routes to interact with IGF-1 receptor, IGF-2 receptor, or the insulin receptor on MSCs
and other cells. IGFBPs (extracellular and/or intracellular actions) can modify IGF actions and affect their stability and degradation. Other
receptors and integrins are expressed in MSCs and can be affected by extracellular microenvironment. MSC differentiation occurs by signal
transduction which controls the shutdown of pluripotency-associated genes, such as OCT4, SOX2, and NANOG, for the upregulation of
differentiation genes. For example, MSCs can give rise to all mesodermal lineages depending on the transcription factor expressed to generate
adipose, cartilage, bone, and muscle. Also, transdifferentiation of MSCs into endodermal and ectodermal lineages can occur, as reported by
in vitro studies.
𝛽-subunits creates high affinity binding sites for signaling
adaptor molecules and substrates. For the ERK1/2 signaling
pathway, SHC interacts directly with the IGF-1R𝛽 which
recruits GRB2 that interacts with SOS that subsequently
activates c-RAS leading to the sequential phosphorylation
of RAF, MEK1/2, and then ERK1/2 [42, 62–66]. To activate
the PI3K/AKT signaling, p85, the regulatory subunit of
PI3K, interacts directly with IGF-1R𝛽 independent of SHC
binding [67]. IRS-1 is a main target of the IGF-1R, implicated
in the mitogenic effect of IGF-1R, inhibition of apoptosis,
and transformation, whereas its downregulation has been
associated with the inhibition of differentiation and the
induction of apoptosis [58, 68].The phosphorylation of IRS-1
amplifies the IGF-1R signaling by indirectly recruiting GRB2
to transduce ERK1/2 signaling [62] or p85 to transduce PI3K
signaling [69]. Therefore, surrounding microenvironmental
inputswould define stem cell behavior depending on receptor
activation and the combination of signaling cascades.
4. The Role of IGFs in
Growth and Development
During development, circulating IGF levels correlate propor-
tionally with placental and fetal weights, and reduced levels
due to poor maternal-nutrition have been suggested to lead
to fetal growth restriction [70]. In human pregnancies, IGFs
play an early role in promoting proliferation/differentiation
and preventing cell apoptosis of various types of placental
cells [61]. In mice, knockout of Igf-1 or Igf-1r causes restricted
growth (<60% of wild-type) and a premature death of
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newborn embryos. Most pups with Igf-1r−/− are unable to
survive due to the lack of functional muscles required for
breathing, while some mouse lines with Igf-1−/− will survive
with deficits in major organs [71–73]. On the other hand,
Igf-2 knockoutmice (indistinguishable between homozygous
and heterozygous) are viable at 60% birthweight of wild-
type [74]. Double mutants for Igf-1 and Igf-2 are severely
growth-deficient (30% of wild-type) and die shortly after
birth of respiratory failure. Although both IGFs have an
additive effect in embryonic development, IGF-1 is more
important in postnatal growth, while IGF-2 is important
for prenatal fetoplacental growth. Hence, IGF-1 and IGF-
2 stimulate both proliferation and terminal differentiation
of many organs and tissues in developing embryos and
adult life. Due to the initial description of Igf-1, Igf-2,
and Igf-1r null mice using classic knockout methodology,
mice with tissue-specific knockout of these genes have been
generated using Cre/loxP conditional knockout strategies
with interesting and variable phenotypes [75–78]. The major
differences between the models are the tissue/cell-specificity
and the timing of the null mutation (prenatal or postnatal).
Most of the conditional targeted models are generated with
gene targeting after birth to allow examination of the role
of Igf-1 and Igf-1r in postnatal development without the
ability to discriminate null mutation in stem or somatic cells.
In classic knockout models, gene targeting occurs in the
embryonic stem cells, allowing us to examine the impact of
Igf genes in stem cells. However, only very few reports are
available investigating the impact of the knockout of Igf-1
and Igf-1r in stem cells. Knockout of Igf-1r in adult neural
stem cells maintains youthful characteristics of the olfactory
bulb neurogenesis within the aging brain by increasing the
cumulative neuroblast production and enhancing neuronal
integration into the olfactory bulb, suggesting a gain of
function during aging [79].
5. The Role of IGFs in MSC
Multipotency and Self-Renewal
MSCs isolated from different tissues, such as bone marrow,
adipose tissue, placental chorionic villi, and fetal membranes,
express and secrete IGF-1 and/or IGF-2 in vitro [80–83]. It
was shown that ectopic IGF-1 expression in MSCs enhances
their proliferation with lower apoptosis [84]. In this study,
autocrine IGF-1 levels maintain an elevated baseline activity
of ERK1/2 signaling required for enhanced self-renewal
(higher OCT4), endodermal (higher CYP51) and mesoder-
mal (higher SM22𝛼) potential, butweakened neuronal poten-
tial (lower Nestin) [84]. Another growth factor which is basic
fibroblast growth factor (bFGF) was shown to be required
in maintaining stemness and proliferation in hESCs [31, 85]
and in MSCs [80, 86, 87]. Further investigation showed that
this bFGF effect was mediated via the IGF system that is
upregulated by an autonomous expression of IGF-1R, IGF-1,
and IGF-2, as shown in umbilical cord MSCs [86]. Although
both IGF-1 and IGF-2 are involved in mediating stem cell
fate changes, IGF-2 appears to be more prominent than IGF-
1 in promoting MSC pluripotency/self-renewal. In hESCs,
one study showed that IGF-2, secreted by spontaneously
differentiated autologous fibroblast-like cells in response to
bFGF, is required to maintain hESC pluripotency and self-
renewal via the signaling of IGF-1R [31]. However, one study
showed that hESCs pluripotency/self-renewal maintenance
can be independent of IGF-2 secretion only when MSCs are
used as a feeder layer [88]. A study, in human dental pulp
MSCs (hDSCs), confirmed that IGF-1R is required for MSC
multipotency and can be regarded as a selection marker for
stemness, just similar to OCT4 and SOX2 [89]. In placental
MSCs (PMSCs), IGF-2 is upregulated by low oxygen tension
and is required tomaintainMSCmultipotency [80, 87]. Also,
in neural stem cells (NSCs), IGF-2 was shown to play an
important role in maintaining self-renewal [90]. In these
NSCs, the IGF-2 self-renewal properties were mediated via
A-isoform of IR (IR-A), independent of IGF-1R or IGF-
2R [91]. For a more detailed review on insulin and IGF
receptor signaling in neural stem cells, please see Ziegler et
al. (2015) [92]. We verified the role of IR-A in PMSC, where
we showed an elevated expression level of IR-A versus IR-B;
and both IGF-1 and IGF-2 promote increased proliferation
and self-renewal with a requirement that both IGF-1R and
IR must be present [80]. Although IGF-1R and IR can form
hybrid receptors, the role of hybrid receptor in maintaining
stem cell fate (ESCs or MSCs) and pluripotency is yet to be
confirmed.
6. Induction of Same-Origin MSCs
towards Different Lineages
In vitro, MSC differentiation can be initiated via extrin-
sic stimulation by growth-factor-mediated differentiation
[93] that requires withdrawing maintenance growth fac-
tors and adding differentiation promoting growth factors
and chemicals [28, 29]. Differentiation factors can include
butylated hydroxyanisole and NGF for neuronal differenti-
ation; BMP-12 for tenocyte differentiation; dexamethasone,
3-isobutyl-1-methylxanthine, insulin, and indomethacin for
adipogenic differentiation; monothioglycerol, HGF, onco-
statin, dexamethasone, FGF4, insulin, transferrin, and sele-
nium for hepatocytic differentiation; b-FGF and VEGF
for endothelial differentiation; TGF-𝛽1, insulin, transferrin,
dexamethasone, and ascorbic acid for chondrogenic dif-
ferentiation; insulin, transferrin, and selenium for skeletal
myogenic differentiation; and dexamethasone, ascorbic acid,
and 𝛽-glycerophosphate for osteogenic differentiation [94–
99]. Therefore, the same MSC population in the mesoderm
exposed to different extrinsic stimuli can initiate differentia-
tion towards a specific cell type by triggering a tissue-specific
transcription factor, such as SOX5/6/9 for chondrocytes,
PPAR𝛾 for adipocytes, MyoD family for myoblasts, and
RUNX2/Osterix for osteoblasts [100]. Moreover, MSCs are
shown to transdifferentiate to lineages outside of the meso-
dermal lineage. In these complex differentiation processes,
IGFs are shown to play a role in fine-tuning transcription fac-
tor expression levels and activity and defining commitment
towards specific lineages from the three germ layers.
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7. The Role of IGFs in Mesenchymal Stem Cell
Fate Specification and Differentiation
7.1. Mesodermal Differentiation
7.1.1. Osteogenesis. IGF-1 and IGF-2 are secreted by skele-
tal bone cells for stimulation of bone formation, growth,
and metabolism and prevent apoptosis in a paracrine/auto-
crine manner [101, 102]. Local overexpression of IGF-1 in
osteoblasts can accelerate the rate of bone formation and
increase the pace of matrix mineralization, which is depen-
dent on IGF-1R [103]. Decoupling of IGF-1R signaling from
IGF-1 is responsible for reduced proliferation/differentiation
in primary osteoblast from osteoporosis patients, hence
causing bone loss [104]. Under nondifferentiation conditions,
IGF-1 transfected human MSCs were able to upregulate
expression of various osteoblast genes [105]. For regeneration,
bone marrow MSCs (BM-MSCs) secrete IGF-1 and the use
of their conditioned media was required to restore alveolar
bone regeneration prior to dental implant placement [106]. In
dental pulpMSCdifferentiation, IGF-1was shown to promote
mTOR signaling pathway in order to trigger the expression of
RUNX2, OCN, OSX, and COL1 [36]. Also, human deciduous
teethMSCswith high osteopotential express and secrete IGF-
2 that is required for differentiation andmineralization [107].
Overall, IGF-1 and IGF-2 play a significant role in MSC
osteogenic differentiation and bone health.
7.1.2. Myogenesis. L6E9 cells (a myoblast cell line used in late
myogenesis studies), when stimulated with IGF-1, have an
initial proliferative response [108]. During rapid cell division,
the myogenic regulatory factors are inhibited, whereas, 30
hours later, the mitogenic effect is suppressed and Myo-
genin expression and activity are increased. Although the
downstream factors in IGF-mediated differentiation are still
under investigation, IGFs can induce myogenic transcription
factors. In contrast, the overexpression of MyoD (a protein
that plays a major role in regulating muscle differentiation)
in C3H 10T1/2 mouse embryonic fibroblast cells induces
IGF-2 expression which in turn activates IGF-1R and its
downstream target AKT [109]. Specifically, IGF-2 is required
for the recruitment and induction of myogenic promoters
and myogenesis [110]. In particular, IGF-2 is required to
allow continued recruitment of MyoD-associated proteins
at the Myogenin promoter [111]. Moreover, IGF-2 specific
binding protein, IGFBP-6, is expressed during embryonic
development inmany different tissues including the ossifying
bones of the cranium, myoblasts, and the motor neurons of
the spinal cord [112].
The potential use of MSCs has been investigated in
treating muscular injury and myocardial infarction. Rat BM-
MSCs have been used as the source of paracrine factors
to treat soleus muscle injury [113]. Pretreatment of MSCs
with IGF-1 improves MSC healing ability by reducing scar
formation, increasing angiogenesis and faster reconstitu-
tion of muscle structure, and improving function [113]. In
another study, injection of BM-MSCs into the cardiac muscle
increased the proliferation andmigration and inhibited apop-
tosis of existing cardiac muscle cells; however, IGF-1 does
not induce myocardial differentiation of these MSCs [114]. In
addition, transplantation of IGF-1-primed MSCs attenuates
cardiac dysfunction, increases the survival of engrafted cells
in the ischemic heart, decreases myocardium cell apoptosis,
and inhibits the expression of inflammation cytokines such
as tumor necrosis factor-alpha (TNF-𝛼), interleukin-1𝛽 (IL-
1𝛽), and IL-6 [115]. The current research into MSCs and IGF
in myogenesis is, therefore, more focused on in vivo muscle
repair than on MSC-differentiated myoblast in transplanta-
tion.
7.1.3. Adipogenesis. In a comparative study between MSCs
from different sources including adipose stem cells (ASCs),
bone marrow stem cells (BMSCs), dermal sheath cells
(DSCs), and dermal papilla cells (DPCs), IGF-1 had the
highest expression and secretion in ASCs compared to
the other populations [116]. Also, IGF1 could promote lin-
eage bias and selection for adipogenic progenitor (CD31−/
CD34+/CD146−) cells at the expense of the less adi-
pogenic cells (CD31−/CD34+/CD146+) [37]. In this pro-
cess, IGF-1 attenuates Wnt/𝛽-catenin signaling by activat-
ing Axin2/PPAR𝛾 pathways to promote the selection for
(CD31−/CD34+/CD146−) cells [37]. In another study, IGF-
1 was shown to alter MSC fate between osteogenic and
adipogenic lineages by its ability to bind and form a complex
with the acid-labile subunit (ALS) [117]. The loss of this IGF-
1/ALS complex shifted differentiation from osteogenesis to
adipogenesis [117].
7.1.4. Chondrogenesis. In an intervertebral disc degeneration
study, it was shown that IGF-1 andTGF-𝛽3work in synergy to
enhance nucleus pulposus-derived mesenchymal stem cells
viability, extracellularmatrix biosynthesis, and differentiation
towards nucleus pulposus cells [118]. Although TGF-𝛽 sig-
naling is known to be important for chondroinductive dif-
ferentiation from MSCs, more studies are showing that IGF-
1 can regulate MSC chondrogenesis independent of TGF-𝛽.
In one study, IGF-1 can induce chondrogenic differentiation
from adipose-derived MSCs with increased collagen type II,
Aggrecan, and SOX9 levels [38]. Similarly, IGF-1 induced
the chondrogenic potential of BM-derivedMSCs stimulating
proliferation, regulating apoptosis, and inducing expression
of chondrogenic markers [119]. In this play of IGF-1 in
chondrogenesis, IRS-1 localization was induced from being
nuclear to being cytoplasmic to shift MSC proliferation to
differentiation [120].
7.2. Ectodermal Differentiation
7.2.1. Corneal and Neurogenesis. IGF-1 plays an important
role in ectodermal lineage differentiation. MSC differenti-
ation towards neural progenitor cells (NPCs) is enhanced
by IGF-1 with increased expression of Nestin and the rate
of cell proliferation, while it inhibits apoptosis and induces
higher terminal differentiation of NPC towards neurons
and glial cells [40]. In another study, the administration
of IGF-1 alone in addition to corneal extract stimulated
differentiation of BM-MSCs into corneal-like cells more
efficiently [39]. Mice with reduced IGF-1R expression in
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the brain in conditional mutant 𝑛𝑒𝑠-𝐼𝑔𝑓1𝑟−/Wt demonstrate
greater neuronal damage following hypoxic-ischemic injury,
suggesting the importance of IGF-1R in neuronal cells,
including neuronal progenitor and stem cells [121]. IGFBP-2
promotes the keratocyte phenotype of differentiating human
corneal fibroblasts from MSCs by increasing the expression
of keratocan and ALDH1A1 and decreasing 𝛼-smoothmuscle
actin [122]. In addition, IGF-1 overexpressing UC-MSCs are
able to differentiate more successfully to neural progenitor
cells producing more Pax6-positive cells and Nestin-positive
cells and could differentiate into astrocytes with higher
efficiency [123].
7.2.2. Epidermal and Dermal Lineages. The role of MSCs and
IGFs has been explored in the treatment of skin ulcers, par-
ticularly challenging clinical conditions like diabetes [124].
In the developing skin, IGF-1 is expressed in the stratum
granulosum, dermal fibroblasts, and the differentiating hair
follicles and sebaceous glands [125]. In particular, IGF-1 is
strongly expressed in the injury area, where it plays an
important role in both epidermal and dermal wound-healing
[126]. Recently, BM-MSCs were used in a rodent model of
diabetic foot ulceration and were demonstrated to improve
wound-healing and to increase the expression of local GFs
including IGF-1, EGF, and MMP2 [127].
7.3. Endodermal Differentiation
7.3.1. Endocrine Pancreas and Liver. MSC differentiation
towards 𝛽-cells, derived by stepwise media formulation, has
not been successful to generate fully functional and glucose-
responsive insulin-secreting 𝛽-cells. However, similar to
treating patients with cardiac infarction, MSC transplanta-
tion into diabetic patients is being investigated. Umbilical
cord MSCs injected in vivo in an induced diabetic rat model
were able to prevent hyperglycemic progression and preserve
islet size and cellularity; IGF-1 secreted by MSCs was respon-
sible for islet viability and insulin secretion in vitro [128].
Therefore, IGF-1 is a prominent trophic factor in pancreatic
islet function and development, whichmay be required for𝛽-
cell differentiation in vitro. In hepatocyte differentiation, IGF-
1 is expressed and required in the liver during development. It
was shown that the addition of IGF-1 to differentiationmedia
induced earlier hepatocyte morphology changes, albumin
and AFP expression, glycogen storage, urea production, and
albumin secretion [41].
8. Crosstalk between the IGF Axis
and Other Signaling Pathways in MSC
Proliferation and Differentiation
Adult MSCs express different genes associated with both
self-renewal and differentiation, including members of the
Notch, TGFB, FGF, WNT, IGF, hedgehog families, and
G-protein coupled receptor-mediated and cAMP-mediated
signaling [129]. Crosstalk between signaling pathways has
been shown to be important for stem cells’ self-renewal and
differentiation; however, specific interactions with the IGF
system are still being delineated in MSCs.
As shown in Figure 1, integrins can play an important
role in IGF signaling. In particular, IGF-1 directly binds
to 𝛼v𝛽3 integrin and induces 𝛼v𝛽3-IGF1-IGF1R ternary
complex formation required for phosphorylation, ERK and
AKT activation, and cell proliferation [130].
In primary oligodendrocyte precursors, IGF-1 signaling
was shown to increase 𝛽-catenin protein abundance via the
IGF-1-induced phosphorylation of AKT and GSK3 required
for an increase in cyclinD1mRNA, proliferation, and survival
[131].
To enhance migration and homing after transplantation,
IGF-1 upregulates the level of the CXCR4, receptor for the
chemokine stromal cell-derived factor-1, and SDF-1, inMSCs
and in turn can accelerate migration [132, 133]. In these
MSCs, CXCR4 upregulation is mediated by the PI3K/AKT
pathway downstream of the activated IGF-1R [133]. In vivo,
MSC preconditioning with IGF-1, before administration, was
shown to be effective in migration and homing which was
required for the restoration of renal function following acute
kidney injury [47].
In bone formation and osteoblast differentiation, IGF-2
was shown to potentiate the bone morphogenetic protein-
9 (BMP-9), which belongs to the transforming growth
factor-𝛽 (TGF-𝛽) superfamily [134]. IGF-2, mediated via
the PI3K/AKT, can potentiate BMP-9-induced activity of
the early osteogenic marker alkaline phosphatase (ALP) and
the expression of later markers such as osteocalcin and
osteopontin in MSCs. On the other hand, IGFBP3 and
IGFBP4 can inhibit the potentiation effect of IGF-2 on BMP-
9-induced ALP activity and matrix mineralization in MSCs
[134].
Also, in osteoblast differentiation of BM-MSCs, hedgehog
(HH) via Gli2 was shown to increase IGF-2 expression
that was acting via the IGF-1R/mTORC2/AKT [135]. IGF-
2-mediated AKT activation served as a positive feedback
loop for enhanced HH transcriptional output by stabilizing
full-length Gli2 due to phosphorylation by AKT. In myo-
genic differentiation, sonic hedgehog (SHH), member of
HH family, was also regarded as positive regulator of IGF-1
signaling in a cooperative additive effect in primary myoblast
proliferation and differentiation via the MAPK/ERK and
PI3K/AKT pathways [136]. In this process, Smoothened, a
SHH effector, can associate with IGF-1R and is required for
IGF-1 action via AKT, especially for differentiation.
Crosstalk between the IGF system and other pathways has
also been explored in cancer stem cells which may not be
dependent on their immediate niche but can give an insight
into normal MSCs [137]. In glioma stem cells (GSC), HH
via Gli1 upregulated the transcriptional activation of IRS-1
which increased GSC sensitivity to IGF-1 stimulation [138].
In lung adenocarcinoma stem-like cells, IGF-1R-mediated
OCT4 expression to form a complex with 𝛽-catenin and
SOX2 was crucial for the self-renewal and oncogenic poten-
tial [139].Other signaling pathways are shown to interact with
the IGF system inmany cell types that are still to be elucidated
in the MSC population and understand their effect in self-
renewal and differentiation.
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Table 1: MSC differentiation protocols with IGFs towards different lineages. Example of MSC differentiation protocols included IGFs in their
differentiation media formulations.
MSC population Differentiation Protocol Reference
Human dental pulp
stem cells Osteoblast-like cells
Osteogenic media supplemented with
0.1 𝜇mol/L dexamethasone, 10mmol/L
b-glycerophosphate, 50 𝜇g/mL ascorbic acid,
and 100 ng/mL of IGF-1.
[36]
Stromal vascular
fraction of adipose
tissue, human adipose
stem/progenitor cells
Adipocyte-like cells StemPro Adipogenesis Differentiation Kitsupplemented with 10 ng/mL of IGF-1. [37]
Human
adipose-derived
mesenchymal cells
Chondrocyte-like
cells
DMEM high glucose supplemented with 1%
FBS, 0.1mM ascorbic acid-2-phosphate, 10−7
dexamethasone, 6.25 𝜇g/mL transferrin,
6.25 ng/mL selenous acid, 10 ng/mL
recombinant human TGF-𝛽1, and 100 ng/mL
recombinant human IGF-1.
[38]
Mouse bone marrow
mesenchymal stem
cells
Corneal-like cells
MSCs were cultured for 3, 7, or 10 days in
complete DMEM with 20% extract from the
corneas and 20 ng/mL IGF-1.
[39]
Rat bone marrow
mesenchymal stem
cells
Neural-like cells
Proliferation media: NeuroCult NS-A
proliferation media specific for rat
supplemented with 20 ng/mL EGF, 20 ng/mL
bFGF, and 100 ng/mL IGF-1. Differentiation
media: NeuroCult supplemented with 10 ng/mL
PDGF-BB for glial induction or 10 ng/mL
rh-BDNF for neuronal differentiation.
[40]
Human bone marrow
mesenchymal stem
cells
Hepatocyte-like cell
Step 1: DMEM low glucose supplemented with
10% FBS, 20 ng/mL of IGF-I, 20 ng/mL of HGF,
and 10−7 M dexamethasone for 7 days. Step 2:
step 1media with 10 ng/mL Oncostatin M for
14 days.
[41]
9. IGF-Expressing MSCs in
Treating Terminal Diseases
Paracrine factors, including IGFs, secreted by MSCs are
shown to play a major role in treating organ-failure-causing
diseases. IGF-expressing MSCs were shown to enhance pro-
liferation, differentiation, and repair of surrounding tissue
in kidney, heart, and pancreas [81–83]. In kidney ischemic-
reperfusion injury, physical interaction between MSC and
kidney tissue was required to promote kidney repair and
not only MSC conditioned media alone [83]. Genetically
engineered IGF-1-MSCs were used to treat liver cirrhosis
in mice [140]. Transplanted MSC induced higher IGF-1
and HGF expression with lowered TGF-𝛽1 levels and less
activation of hepatic satellite cells. IGF-1 effect was evident by
lowered collagen expression andfibrosiswithmore parenchy-
mal cell proliferation as indication of liver regeneration.
Following myocardial infarction, it was shown that adult
human epicardium-derived cells and cardiomyocyte progen-
itor cells synergistically improve cardiac function, probably
instigated by complementary paracrine actions [141]. In fact,
cotransplantation of unmodified MSC plus cardiovascular
progenitors had elevated expression of factors promoting
cardiac repair specifically IGF1 that promoted expression of
prosurvival and angiogenesis genes in human cells [142].
In induced diabetes STZ mice, MSC helped to attenuate
abnormal function of adipocytes, which are involved in
cutaneous wound-healing, by IGF-1 secretion [143]. IGF-1
in these mice helped in activating PI3K/AKT and GLUT4
which improved glucose uptake and insulin sensitivity, there-
fore improving diabetic wound-healing. In hepatocellular
carcinoma (HCC) treatment, fetal humanMSCs conditioned
mediawere used to inhibit cell growth [144]. It was discovered
that the conditioned media contained high levels of IGFBPs
which sequestered IGFs and reduced IGF-1R and AKT
activation, leading to cell cycle arrest in HCC. These tumor-
specific effects were not observed in matched hepatocytes or
patient-derivedmatched normal tissue. In all these examples,
MSCs expressing IGF system components are being used in
enhancing tissue repair of failing organs, fighting cancer, and
ameliorating diabetes.
10. Critical Use of IGF and Insulin in Cell
Culture Conditions
Addition of IGFs to differentiation media leads to earlier
commitment and higher onset of differentiation in several
lineages including endothelial, corneal, neural, chondrocyte,
adipocyte, hepatocytes, and osteoblast cells (Table 1). In
this context, a typical concentration of 10–100 ng/mL of
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IGF-1 is sufficient to activate only the IGF-1R and not the
IR. On the other hand, not much attention is given to
receptor binding affinity of IGF-1R versus IR, when insulin
is used in maintenance or differentiation conditions. The
inclusion in commercial biological products for stem cell
research of nonphysiological concentrations of insulin (0.5, 5,
and 10 𝜇g/mL) for MSC differentiation media is 100–1,000x
higher than highest insulin concentration in serum [145].
High concentrations of insulin (≥1 𝜇g/mL) not only activate
IR but also activate IGF-1R [44, 145]. Therefore, using such
high insulin concentrations in defined media, which can be
a substitute to IGFs, cannot distinguish whether the effect
is mediated via IGF-1R or IR signaling pathways and studies
describing the effect of IGFs in growth and/or differentiation
of stem cells in “defined medium” should recognize this
potential confounding effect.
11. Summary and Conclusions
IGFs are among the earliest growth factors to be expressed
in a developing embryo as early as in preimplantation
embryos and putatively act as autocrine/paracrine factors on
many developing cells including stem cells. They form an
important component of the stem cell niche.Their expression
is ubiquitous in many cell types; however, they are most
abundant in the cells and tissues of mesodermal origin.Thus,
MSCs are both the source and target of IGFs during devel-
opment and likely play important roles in the maintenance
of pluripotency as well as determining their fate to lineages
of all three germ layers. Recent evidence also suggests the
potential discriminating roles of IGF-1 and IGF-2 in MSCs
and progenitor cells of different tissues. As MSCs are being
investigated as being important for cellular replacement and
regenerative therapies, delineating the roles of endogenous as
well as exogenous IGFs in MSC growth and differentiation
will be critical in developing these cellular therapies towards
treatment of many degenerative diseases that have no viable
therapeutic options at present.
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